uniQure CompletesEnrollment In First Cohort Of Phase I/II Clinical Trial Of AMT-130 For The Treatment Of Huntington's Disease
UniQure shares are trading higher after Mizuho upgraded the stock from Neutral to Buy and announced a price target of $52 per share.
UniQure upgraded to buy from neutral at Mizuho, price target $52
uniQure Price Target Announced at $52.00/Share by Mizuho
uniQure analyst ratings
Mizuho Upgrades uniQure to Buy, Announces $52 Price Target
UniQure shares are trading higher after the company announced that its Hemophilia B Gene Therapy is unlikely to be causing liver cancer which was earlier reported in one patient.
Uniqure's Hemophilia B Gene Therapy Unlikely To Be Cause Of Liver Cancer Reported In One Patient
12 Health Care Stocks Moving In Monday's Pre-Market Session
uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma in Hemophilia B Gene Therapy Program